E Toubi
Overview
Explore the profile of E Toubi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1714
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schichter-Konfino V, Mubariki R, Toubi E, Vadasz Z
Front Allergy
. 2024 Oct;
5:1464466.
PMID: 39416263
Background: Omalizumab (OMA) was the first FDA-approved biological drug for severe chronic spontaneous urticaria (CSU), and until today is the only beneficial and truly safe one. The objectives were: To...
2.
Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui I, Aygoren-Pursun E, et al.
Arerugi
. 2023 Sep;
72(8):1084.
PMID: 37730355
No abstract available.
3.
Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui I, Aygoren-Pursun E, et al.
Arerugi
. 2023 May;
72(3):237-272.
PMID: 37225467
No abstract available.
4.
Sabag D, Matanes L, Bejar J, Sheffer H, Barzilai A, Church M, et al.
Clin Exp Allergy
. 2020 May;
50(7):799-804.
PMID: 32412136
Background: Chronic spontaneous urticaria (CSU) is considered an autoimmune disorder in 50% of cases at least, in which T- and mast cell mediators are considered to be the primary cause...
5.
Kudryavtsev I, Serebriakova M, Starshinova A, Zinchenko Y, Basantsova N, Malkova A, et al.
Sci Rep
. 2020 Jan;
10(1):1059.
PMID: 31974463
Sarcoidosis is a systemic granulomatous disease that develops due to the Th1, Th17 and Treg lymphocytes disturbance. There is an assumption, that B cells and follicular T-helper (Tfh) cells may...
6.
Zuberbier T, Aberer W, Asero R, Abdul Latiff A, Baker D, Ballmer-Weber B, et al.
Allergy
. 2018 Jan;
73(7):1393-1414.
PMID: 29336054
This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on...
7.
Vadasz Z, Elbirt D, Radian S, Bezalel-Rosenberg S, Mahlab-Guri K, Toubi E, et al.
Clin Immunol
. 2017 Sep;
191:88-93.
PMID: 28917721
Introduction: Semaphorin-4D (CD100), generated by CD4/CD8 T-cells and its receptor on B cells - CD72, play a role in immune regulation. Both have soluble forms - sCD100/sCD72. Methods: sCD100 and...
8.
Gimenez-Arnau A, Toubi E, Marsland A, Maurer M
J Eur Acad Dermatol Venereol
. 2016 Jun;
30 Suppl 5:25-32.
PMID: 27286500
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria...
9.
Staubach P, Zuberbier T, Vestergaard C, Siebenhaar F, Toubi E, Sussman G
J Eur Acad Dermatol Venereol
. 2016 Jun;
30 Suppl 5:16-24.
PMID: 27286499
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Despite the clear international guideline, there remain a number of...
10.
Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica G, Church M, et al.
Allergy
. 2016 Apr;
71(8):1210-8.
PMID: 27038243
Background: GA²LEN, the Global Allergy and Asthma European Network, has recently launched a program for the development, interaction, and accreditation of centers of reference and excellence in special areas of...